Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq

Regulatory News: Celyad Oncology (Euronext Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced

Related Keywords

Belgium ,Mont Saint Guibert ,Waals Gewest ,United States ,New York ,American ,Caroline Lonez ,David Georges ,Us Securities Exchange ,Exchange Commission ,Business Development ,Company Adss ,Company On ,Wrd Communications ,Citibank ,Nasdaq ,Adss Of The Company ,Regulatory News ,Euronext Nasdaq ,American Depositary Shares ,Nasdaq Global Market ,American Depositary Receipt ,Nasdaq Stock Market ,Nasdaq Listing Rule ,Exchange Act ,Celyad Oncology ,Private Securities Litigation Reform Act ,Annual Report ,Oncology Contacts ,Celyad ,Ncology ,Nnounces ,Intent ,Unvoluntarily ,Relist ,Repository ,Hares ,Rom ,